Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.
How this was made
The 30-second read
Why it matters
The steep revenue target creates execution risk, likely influencing short‑term price action and investor sentiment.
Market read
Primary earnings disclosure for a micro‑cap; relevance driven by aggressive guidance and product pipeline.
What to watch
Potential reimbursement changes and competitive pressure from larger eye‑care firms could further strain H2 performance.
Background
Harrow Inc. (NASDAQ:HROW) is a specialty ophthalmic device company reporting its first half 2026 results and full‑year outlook.
Ticker impact
Harrow reported H1 2026 revenue of $115M and reaffirmed FY guidance of $350M‑$365M, requiring a steep $235M‑$250M second‑half ramp.
potential downside pressure if second‑half execution falls short
The company must more than double H2 revenue, a significant execution risk for a micro‑cap.
Market effects
Highlights volatility in the ophthalmology/ocular‑therapy sector as peers watch Harrow's execution.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global impact beyond niche eye‑care market.
Counterpoint
If Harrow successfully scales TYRVAYA and improves margins, the guidance may be overly conservative.
Key entities
- companyHarrow Inc.
Subject of the earnings release and guidance.
- productTYRVAYA
Pending nasal‑spray dry eye treatment expected to add $30M+ revenue in 2027.
